Pearl Diagnostics is a Baltimore-based in vitro diagnostics company spun out of Johns Hopkins University that develops non-invasive urine tests to detect life-threatening lung infections. Its proprietary Smart Antibody technology identifies circulating microbial extracellular vesicles, and its lead product, the MycoMEIA Aspergillus Assay, became the first urine-based test to win FDA 510(k) clearance for aiding diagnosis of invasive aspergillosis. The company raised an $11.2M Series A in March 2026 to commercialize in the US and expand across Europe.
G-Tech Medical builds the GutTracker, a thin wireless wearable patch its team calls an 'EKG for the Gut.' Worn on the abdomen for up to six days at home, the patch reads the faint electrical signals that drive the stomach, small intestine, and colon, then streams them over Bluetooth to the cloud, where algorithms turn the noise into patient-specific motility data. The Mountain View company aims to replace short, single-organ, in-clinic tests with continuous, whole-gut measurement so physicians can finally see how a digestive system actually behaves day to day.